Literature DB >> 7641420

Control pathways of the 67 kDa laminin binding protein: surface expression and activity of a new ligand binding domain.

T H Landowski1, S Uthayakumar, J R Starkey.   

Abstract

A number of papers have been published on the clinical correlation of the expression of the 67 kDa laminin binding protein (LBP) with the metastatic potential of solid tumors. Both mRNA and protein expression levels have been reported, but both the relationship between them and the molecular nature of the 67 kDa surface product remain unclear. We have utilized a homotypic overexpression system to investigate the cell surface presentation of the 67 kDa LBP and the contribution of this protein to the invasive phenotype of cultured cell lines. We report here that the cellular mRNA levels do not directly reflect the levels of the 67 kDa LBP observed on the cell surface in this overexpression system. Methotrexate amplification of transfected plasmids expressing the 67 kDa LBP leads to an initial elevation of both the LBP mRNA and surface protein levels. This is accompanied by an altered, more flattened, cell morphology. Later, apparent adaptation of the cells to methotrexate is accompanied by a down-regulation of the surface expression of the protein. mRNA levels, however, remain elevated. A nine amino acid sequence, CDPGYIGSR (peptide 11), within the beta chain of laminin 1 has been identified as a probable binding domain for the 67 kDa LBP. Previous studies have identified a region of the 67 kDa LBP which may be involved in laminin interaction, although not necessarily via the peptide 11 domain. We have identified a second site within the amino acid coding sequence of the 67 kDa LBP which also shows biological activity both in vitro and in vivo. A peptide with this sequence, LBP residues 205-229, binds laminin-1 in a peptide 11 inhibitable manner. The receptor-derived peptide modulates invasion of basement membrane matrix in vitro and inhibits experimental lung colony formation when injected along with B16BL6 mouse melanoma cells. However, pretreatment of the melanoma cells with the peptide enhances lung colony formation. Thus, the interaction of the 67 kDa LBP with basement membrane matrix appears to involve a complex series of events including multiple adhesive sites and tight regulation of cell surface expression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7641420     DOI: 10.1007/bf00121912

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  45 in total

1.  Characterization of two monoclonal antibodies directed against the 67 kDa high affinity laminin receptor and application for the study of breast carcinoma progression.

Authors:  S Martignone; R Pellegrini; E Villa; N N Tandon; A Mastroianni; E Tagliabue; S Ménard; M I Colnaghi
Journal:  Clin Exp Metastasis       Date:  1992-11       Impact factor: 5.150

2.  Interactions of a laminin-binding peptide from a 33-kDa protein related to the 67-kDa laminin receptor with laminin and melanoma cells are heparin-dependent.

Authors:  N H Guo; H C Krutzsch; T Vogel; D D Roberts
Journal:  J Biol Chem       Date:  1992-09-05       Impact factor: 5.157

3.  Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression.

Authors:  A D'Errico; S Garbisa; L A Liotta; V Castronovo; W G Stetler-Stevenson; W F Grigioni
Journal:  Mod Pathol       Date:  1991-03       Impact factor: 7.842

4.  Identification of a second active site in laminin for promotion of cell adhesion and migration and inhibition of in vivo melanoma lung colonization.

Authors:  H K Kleinman; J Graf; Y Iwamoto; M Sasaki; C S Schasteen; Y Yamada; G R Martin; F A Robey
Journal:  Arch Biochem Biophys       Date:  1989-07       Impact factor: 4.013

5.  A new in vitro assay for quantitating tumor cell invasion.

Authors:  L A Repesh
Journal:  Invasion Metastasis       Date:  1989

Review 6.  The laminins: a family of basement membrane glycoproteins important in cell differentiation and tumor metastases.

Authors:  H K Kleinman; B S Weeks; H W Schnaper; M C Kibbey; K Yamamura; D S Grant
Journal:  Vitam Horm       Date:  1993       Impact factor: 3.421

7.  Amphipathic analysis and possible formation of the ion channel in an acetylcholine receptor.

Authors:  J Finer-Moore; R M Stroud
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

8.  Increased expression of the laminin receptor in human colon cancer.

Authors:  V Cioce; V Castronovo; B M Shmookler; S Garbisa; W F Grigioni; L A Liotta; M E Sobel
Journal:  J Natl Cancer Inst       Date:  1991-01-02       Impact factor: 13.506

9.  Enhancement of metastatic potential of murine and human melanoma cells by laminin receptor peptide G: attachment of cancer cells to subendothelial matrix as a pathway for hematogenous metastasis.

Authors:  G Taraboletti; D Belotti; R Giavazzi; M E Sobel; V Castronovo
Journal:  J Natl Cancer Inst       Date:  1993-02-03       Impact factor: 13.506

10.  Increased mRNA expression of a laminin-binding protein in human colon carcinoma: complete sequence of a full-length cDNA encoding the protein.

Authors:  H K Yow; J M Wong; H S Chen; C G Lee; S Davis; G D Steele; L B Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

View more
  10 in total

1.  Conformational switch of a flexible loop in human laminin receptor determines laminin-1 interaction.

Authors:  Carmen Di Giovanni; Alessandro Grottesi; Antonio Lavecchia
Journal:  Eur Biophys J       Date:  2012-03       Impact factor: 1.733

Review 2.  Structure-guided identification of a laminin binding site on the laminin receptor precursor.

Authors:  Kelly V Jamieson; Stevan R Hubbard; Daniel Meruelo
Journal:  J Mol Biol       Date:  2010-10-30       Impact factor: 5.469

Review 3.  Looking into laminin receptor: critical discussion regarding the non-integrin 37/67-kDa laminin receptor/RPSA protein.

Authors:  Vincent DiGiacomo; Daniel Meruelo
Journal:  Biol Rev Camb Philos Soc       Date:  2015-01-28

4.  Genetic identification of antigens exposed in damaged endothelial cells as laminin-binding proteins.

Authors:  D C Ireland; E L Spring; E Moiseeva; D P de Bono
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

5.  Extraribosomal functions associated with the C terminus of the 37/67 kDa laminin receptor are required for maintaining cell viability.

Authors:  J Scheiman; K V Jamieson; J Ziello; J-C Tseng; D Meruelo
Journal:  Cell Death Dis       Date:  2010       Impact factor: 8.469

6.  Diminution of 37-kDa laminin binding protein expression reduces tumour formation of murine lung cancer cells.

Authors:  K Satoh; K Narumi; T Abe; T Sakai; T Kikuchi; M Tanaka; T Shimo-Oka; M Uchida; F Tezuka; M Isemura; T Nukiwa
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

7.  Laminin receptor 37/67LR regulates adhesion and proliferation of normal human intestinal epithelial cells.

Authors:  Taoufik Khalfaoui; Jean-François Groulx; Georges Sabra; Amel GuezGuez; Nuria Basora; Patrick Vermette; Jean-François Beaulieu
Journal:  PLoS One       Date:  2013-08-22       Impact factor: 3.240

8.  Interactions of the 67 kDa laminin receptor and its precursor with laminin.

Authors:  Aliya Fatehullah; Caroline Doherty; Géraldine Pivato; George Allen; Lynda Devine; John Nelson; David J Timson
Journal:  Biosci Rep       Date:  2009-11-10       Impact factor: 3.840

9.  The folded and disordered domains of human ribosomal protein SA have both idiosyncratic and shared functions as membrane receptors.

Authors:  Nora Zidane; Mohamed B Ould-Abeih; Isabelle Petit-Topin; Hugues Bedouelle
Journal:  Biosci Rep       Date:  2012-12-20       Impact factor: 3.840

10.  Identification of the Neuroinvasive Pathogen Host Target, LamR, as an Endothelial Receptor for the Treponema pallidum Adhesin Tp0751.

Authors:  Karen V Lithgow; Brigette Church; Alloysius Gomez; Emily Tsao; Simon Houston; Leigh Anne Swayne; Caroline E Cameron
Journal:  mSphere       Date:  2020-04-01       Impact factor: 4.389

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.